Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glaxo/SB Merger Talks Resume After Management, Manufacturing Changes

Executive Summary

Manufacturing streamlining initiatives undertaken by Glaxo Wellcome and SmithKline Beecham in 1999 may have already begun the cost savings that can be expected from the combination of the British firms.

You may also be interested in...



GlaxoSmithKline Selects European Head Witty To Succeed Garnier As CEO

GlaxoSmithKline's incoming CEO Andrew Witty - the current president of European pharmaceuticals -brings to the post experience with cost-effectiveness that could prove an asset as comparative and cost-effectiveness become increasingly important to the U.S pharmaceutical industry

GlaxoSmithKline Selects European Head Witty To Succeed Garnier As CEO

GlaxoSmithKline's incoming CEO Andrew Witty - the current president of European pharmaceuticals -brings to the post experience with cost-effectiveness that could prove an asset as comparative and cost-effectiveness become increasingly important to the U.S pharmaceutical industry

Glaxo/SB Supply Chain Alignment Will Ease Second Merger Attempt - Garnier

The second attempt at a merger of SmithKline Beecham and Glaxo Wellcome is more likely to succeed because the companies have aligned their manufacturing operations in the two years since the first engagement, CEO-designate Jean-Pierre Garnier, PhD, told the House of Commons Science & Technology Select Committee Feb. 22 in London.

Related Content

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel